Rituximab-abbs, which is biosimilar to rituximab, is now available in the U.S. to treat specific cancers…
Innate Immune Response Predicts Development of Non-Hodgkin’s Lymphoma in Sjögren’s Syndrome
The P2X7 receptor inflammasome axis may have a role in the pathogenesis of Sjögren’s syndrome and non-Hodgkin’s lymphoma. According to new research, patients with Sjögren’s syndrome who developed non-Hodgkin’s lymphoma had an increased expression of the P2X7R-inflammasome axis and the glandular expression of IL-18, suggesting a possible novel biomarker…